An experimental human papillomavirus vaccine made by Merck could offer a boost to the vaccine market, but the company will have to use effective marketing efforts to ensure uptake, according to a new study.
While rates of human papillomavirus infection among girls ages 14 years to 19 years have dropped by half since the Centers for Disease Control and Prevention started recommending routine vaccination against it seven years ago, rates of vaccination have not increased, the agency said.
As new state legislation takes effect Monday to help bring greater patient access to vaccines, Walgreens has significantly expanded vaccine availability at all of its 204 locations across Indiana, the retailer announced.
Only 15.5% of college students know that condoms don't fully protect a person from contacting the human papillomavirus, and this lack of knowledge can lead students to a false sense of security in their sexual practices, according to a new study in Radiologic Technology, a journal published by the American Society of Radiologic Technologists.
As pharmacies become increasingly involved in flu shots, retail-based clinics are expanding into other areas of vaccination — such as vaccines to help protect against human papillomavirus, meningitis and pneumonia — to further meet the healthcare needs of patients.
According to an article in the November/December issue of the journal Medical-Surgical Nursing, rates of HIV/AIDS, herpes, syphilis, human papilloma virus and other STDs are climbing steadily across men and women older than 50 years.
Health experts have expressed fear that Republican presidential candidate Michele Bachmann's comments about the human papillomavirus vaccine could set back progress in vaccinations, according to published reports.
Increases in vaccination rates for the human papillomavirus are trailing increases in rates for two other vaccines recommended for teens and preteens, according to data from the Centers for Disease Control and Prevention released Thursday.
Merck on Wednesday announced that the Food and Drug Administration has approved Gardasil [human papillomavirus quadrivalent (types 6, 11, 16 and 18) vaccine, recombinant] for the prevention of anal cancer in males and females 9 to 26 years of age.